



Imaging biomarkers are key to detecting and treating cancer

Press Release

MEDIAN Technologies Announces New €568,000 Project Award *

MEDIAN Technologies confirms its commercial dynamics with a newly awarded project for image management in a phase II clinical trial for lung cancer.

Sophia Antipolis, France – September 19, 2013 – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced it has been selected to provide imaging solutions and services in a phase II clinical trial for non-small cell lung cancer. This trial is sponsored by a global biopharmaceutical company.

As part of the project, imaging data would be acquired in clinical sites based in three Asian countries: China, Korea and Taiwan. Anticipated total enrollment would be 200 patients with a forecasted clinical trial start in 2015.

Within the framework of the study, MEDIAN would provide a set of imaging services, enabling imaging data collection and quality control. Furthermore, MEDIAN would manage the image independent reviews performed by radiologists using the MEDIAN LMS platform.

The project, awarded through MEDIAN alliance with its strategic partner, would represent a contract of €568,000 (eq. \$755,000) for MEDIAN.

Since the beginning of 2013, MEDIAN Technologies has recorded €3.7M (eq. \$4.9M) of orders, including €0.8M of firm orders and €2.9M of project awards*.

“We are very proud of this new success with one of the leading pharmaceutical companies worldwide. This project clearly demonstrates the relevance of our strategic partnerships, which enable us to have a global reach” said MEDIAN’s Chief Executive Officer, Fredrik Brag.

[*] A project award is a notification announcing that the solution provided the company has been selected for the project. A binding contract should be signed within the 18 months following the award.

ALMDT
LISTED
NYSE
ALTERNEXT

About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS



MEDIAN

Imaging biomarkers are key to detecting and treating cancer

solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Canon for the development of new technologies, and a strategic partnership with Quintiles to offer integrated imaging services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary in the Boston area.

MEDIAN has received the label "Innovative company" by OSEO and is listed on NYSE Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).

For more information on MEDIAN, please visit: www.mediantechologies.com

CONTACTS

MEDIAN Technologies

Fredrik Brag, CEO
+33 492 906 582
fredrik.brag@mediantechnologies.com

Press

ALIZE RP
Caroline Carmagnol
+ 33 664 189 959
caroline@alizerp.com

Investors

ACTIFIN
Anaïs de Scitivaux
+ 33 156 881 114
adescitivaux@actifin.fr

Christian Berg
+ 33 170 225 386
christian@alizerp.com